Business
AXIM® Biotechnologies Signs Supply Agreement to Register Cannabinoid Oral Care Products in Clinical Trials for Gingivitis and Gum Disease
AXIM® Biotechnologies Signs Supply Agreement to Register Cannabinoid Oral Care Products in Clinical Trials for Gingivitis and Gum Disease.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\nNEW YORK, June 25, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and development, today announced that products from its oral care line, including its cannabinoid-based mouthwash and toothpaste, were included in registration for clinical trials through the Australian and New Zealand Clinical Trial Registry.\n The trials were registered by Impression Healthcare Limited (“Impression”), Australia’s largest home dental impression company, which plans to conduct a phase 2a randomized controlled clinical trial to evaluate the clinical safety and efficacy of the products on 40 people suffering from gingivitis and gum disease. Trial participants will use the toothpaste and mouthwash three times a day over 30 days and will be monitored for gum inflammation and overall gum health. “As a mid-stage biotech company, we found it strategic and necessary to partner with larger organizations who are experts in their respective fields in order to bring AXIM products to a much larger worldwide audience. This clinical trial registration through Impression is a tangible example of this methodology working,” said AXIM® Biotech CEO John W. Huemoeller II. “Navigating the various regulatory agencies around the world in order to conduct clinical research on our products is both time-consuming and costly. Partnering with companies like Impression allows for AXIM’s products to be researched on a much faster and more cost-effective basis. We are extremely excited to reveal what we hope to be successful results that only further AXIM’s value-proposition as a leader in pharmaceutical quality cannabinoid-based products.” According to Impression, about 20 percent of the Australian population suffers from moderate to severe gum disease – equating to around five million people. In residents 55 or older, the number of those suffering from gum disease in the country increases to an estimated 40 percent. “Formal registration of the gingivitis and periodontitis trial represents significant progress in Impressions’ medicinal cannabis activities and is the culmination of many months of work by our team and research partners,” said Impr...